Neocitec (Vinorelbine)

Vinorelbine, the active ingredient in Neocitec, is a Vinca alkaloid presented as an injection solution for intravenous use. It is employed in the treatment of adult patients with non‑small cell lung cancer and breast cancer, where it interferes with cell division to help control tumor growth.

GNH USA supplies Neocitec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality‑controlled shipments that meet EU regulatory standards. Our distribution network includes cold‑chain logistics where required and provides full documentation for import compliance.

Vinorelbine is used in oncology to target rapidly dividing tumor cells in specific cancer types.

- Non‑small cell lung cancer: improves disease control and may extend survival in advanced cases. - Breast cancer (early or metastatic): used in combination regimens to reduce tumor burden and delay progression. - Metastatic breast cancer: provides palliation and contributes to overall response rates when combined with other chemotherapeutics.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: gastrointestinal upset common after infusion. - Fatigue: persistent tiredness affecting daily activities. - Constipation: decreased bowel movements. - Alopecia: hair thinning or loss. - Mild peripheral neuropathy: tingling sensations in extremities.

Serious or Rare Side Effects: - Severe neutropenia with fever (febrile neutropenia). - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Anaphylactic reactions: sudden severe allergic response. - Cardiac toxicity: arrhythmias or decreased cardiac function. - Severe hypotension: sudden drop in blood pressure during infusion.

Vinorelbine requires careful monitoring and specific safety measures before and during therapy.

- Monitor blood counts: perform regular CBC to detect neutropenia early. - Assess liver function: adjust dosing in patients with hepatic impairment. - Evaluate pulmonary status: use caution in patients with pre‑existing lung disease. - Avoid concurrent myelosuppressive agents: reduces risk of severe bone‑marrow suppression. - Adjust for renal impairment: consider dose modification in reduced kidney function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase vinorelbine exposure and toxicity. - Concurrent myelosuppressive chemotherapy agents: heighten risk of severe neutropenia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug levels, decreasing effectiveness. - Anticoagulants (e.g., warfarin): increased bleeding risk, monitor coagulation parameters. - Live vaccines: immunosuppression may diminish vaccine efficacy, avoid during treatment.